RU2010113969A - Применение trp-6-трипторелина и d-leu6-лейпролида в качестве терапевтических средств - Google Patents

Применение trp-6-трипторелина и d-leu6-лейпролида в качестве терапевтических средств Download PDF

Info

Publication number
RU2010113969A
RU2010113969A RU2010113969/15A RU2010113969A RU2010113969A RU 2010113969 A RU2010113969 A RU 2010113969A RU 2010113969/15 A RU2010113969/15 A RU 2010113969/15A RU 2010113969 A RU2010113969 A RU 2010113969A RU 2010113969 A RU2010113969 A RU 2010113969A
Authority
RU
Russia
Prior art keywords
diseases
disease
trp
arg
ser
Prior art date
Application number
RU2010113969/15A
Other languages
English (en)
Inventor
Дориан БЕВЕК (DE)
Дориан БЕВЕК
Фабио КАВАЛЛИ (CH)
Фабио КАВАЛЛИ
Вера КАВАЛЛИ (CH)
Вера КАВАЛЛИ
Геральд БАХЕР (DE)
Геральд БАХЕР
Original Assignee
Мондобайотек Лабораториз Аг (Li)
Мондобайотек Лабораториз Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мондобайотек Лабораториз Аг (Li), Мондобайотек Лабораториз Аг filed Critical Мондобайотек Лабораториз Аг (Li)
Publication of RU2010113969A publication Critical patent/RU2010113969A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)

Abstract

1. Комбинация пептидов Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 и Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-D-Leu-Arg-Pro-NHEt или их солей или гидратов. ! 2. Комбинация по п.1, где пептиды содержатся в комбинации в количестве от 30% по массе к 70% по массе до 70% по массе к 30% по массе. ! 3. Комбинация по п.1 для применения в лекарственном средстве. ! 4. Применение пептида Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 или комбинации по п.1 или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 5. Применение пептида по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из инфекции Streptococcus pneumoniae, связанных с инфекцией Streptococcus pneumoniae заболеваний, а именно гемолитического уремического синдрома, пневмонии, менингита, осложнения кистозного фиброза, заболеваний среднего уха, инфекций в кровотоке, инфекций синуса и уха, острого синусита, среднего отита, остеомиелита, септического артрита, эндокардита, перитонита, перикардита и абсцесса мозга. ! 6. Применение пептида Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 7. Применение пептида Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 для получения лиофилизированного состава или буферного жидкого состава. ! 8. Фармацевтическая композиция, со

Claims (12)

1. Комбинация пептидов Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 и Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-D-Leu-Arg-Pro-NHEt или их солей или гидратов.
2. Комбинация по п.1, где пептиды содержатся в комбинации в количестве от 30% по массе к 70% по массе до 70% по массе к 30% по массе.
3. Комбинация по п.1 для применения в лекарственном средстве.
4. Применение пептида Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 или комбинации по п.1 или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
5. Применение пептида по п.4, где злокачественная опухоль, аутоиммунное заболевание, фиброз, воспалительное заболевание, нейродегенеративное заболевание, инфекционное заболевание, заболевание легких, заболевание сердца и сосудов или болезнь обмена веществ выбраны из инфекции Streptococcus pneumoniae, связанных с инфекцией Streptococcus pneumoniae заболеваний, а именно гемолитического уремического синдрома, пневмонии, менингита, осложнения кистозного фиброза, заболеваний среднего уха, инфекций в кровотоке, инфекций синуса и уха, острого синусита, среднего отита, остеомиелита, септического артрита, эндокардита, перитонита, перикардита и абсцесса мозга.
6. Применение пептида Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
7. Применение пептида Pyr-His-Trp-Ser-Tyr-Trp-Leu-Arg-Pro-Gly-NH2 для получения лиофилизированного состава или буферного жидкого состава.
8. Фармацевтическая композиция, содержащая комбинацию по п.1 совместно с, по меньшей мере, одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
9. Фармацевтическая композиция по п.8 в форме лиофилизата или жидкого буферного раствора.
10. Фармацевтическая композиция по п.8 или 9, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
11. Фармацевтическая композиция по п.8 или 9 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
12. Фармацевтическая композиция по п.8, или 9, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезни обмена веществ.
RU2010113969/15A 2007-09-11 2008-09-09 Применение trp-6-трипторелина и d-leu6-лейпролида в качестве терапевтических средств RU2010113969A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07017750 2007-09-11
EP07017750.6 2007-09-11

Publications (1)

Publication Number Publication Date
RU2010113969A true RU2010113969A (ru) 2011-10-20

Family

ID=40293586

Family Applications (5)

Application Number Title Priority Date Filing Date
RU2010114059/15A RU2010114059A (ru) 2007-09-11 2008-09-09 Применение фибронектинового фрагмента (196-203) в качестве терапевтического средства
RU2010113969/15A RU2010113969A (ru) 2007-09-11 2008-09-09 Применение trp-6-трипторелина и d-leu6-лейпролида в качестве терапевтических средств
RU2010114034/15A RU2010114034A (ru) 2007-09-11 2008-09-09 Терапевтическое применение нейропептида ei и acth 7-38 и их комбинаций
RU2010113989/15A RU2010113989A (ru) 2007-09-11 2008-09-09 Применение пептида в качестве терапевтического средства
RU2010114007/15A RU2010114007A (ru) 2007-09-11 2008-09-09 Применение комбинации пептидов cart в качестве терапевтического средства

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2010114059/15A RU2010114059A (ru) 2007-09-11 2008-09-09 Применение фибронектинового фрагмента (196-203) в качестве терапевтического средства

Family Applications After (3)

Application Number Title Priority Date Filing Date
RU2010114034/15A RU2010114034A (ru) 2007-09-11 2008-09-09 Терапевтическое применение нейропептида ei и acth 7-38 и их комбинаций
RU2010113989/15A RU2010113989A (ru) 2007-09-11 2008-09-09 Применение пептида в качестве терапевтического средства
RU2010114007/15A RU2010114007A (ru) 2007-09-11 2008-09-09 Применение комбинации пептидов cart в качестве терапевтического средства

Country Status (9)

Country Link
US (6) US20100216724A1 (ru)
EP (6) EP2207560A2 (ru)
JP (5) JP5385276B2 (ru)
KR (5) KR20100058556A (ru)
AT (1) ATE553772T1 (ru)
AU (5) AU2008306130A1 (ru)
CA (5) CA2698666A1 (ru)
RU (5) RU2010114059A (ru)
WO (16) WO2009043518A2 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2362604B1 (es) * 2009-12-22 2012-06-28 Bcn Peptides, S.A. Formulación tópica oftálmica de péptidos.
CN105456206B (zh) * 2010-01-13 2018-12-14 益普生制药股份有限公司 用于延缓释放生长抑素类似物的药物组合物的制备方法
JP6267638B2 (ja) * 2011-09-26 2018-01-24 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーＧａｌｅｒａ Ｌａｂｓ， Ｌｌｃ 疾患の治療方法
WO2013067420A1 (en) * 2011-11-03 2013-05-10 Tumlin James A Acth for treatment of kidney disease
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
AU2013209862A1 (en) * 2012-01-17 2014-09-04 Tyme, Inc. Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
WO2013142229A1 (en) * 2012-03-19 2013-09-26 President And Fellows Of Harvard College Designing novel peptides for inducing fibronectin matrix assembly
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
RU2528337C1 (ru) * 2013-09-25 2014-09-10 Халлар Абдумуслимович Алиханов Средство для лечения аутоиммунных заболеваний
JP7095990B2 (ja) 2014-09-18 2022-07-05 シーダーズ－サイナイ メディカル センター 線維症を治療するための組成物及び方法
JP2021501796A (ja) * 2017-11-02 2021-01-21 タルシウス ファーマ リミテッド 眼炎症を治療するためのホスホリルコリン−タフトシン複合体
CN110438066B (zh) * 2019-08-19 2021-01-12 杭州百凌生物科技有限公司 一种可稳定传代的可悬浮培养的哺乳动物细胞系293 c18p及其制备方法和应用
CN115150565B (zh) * 2022-09-01 2023-01-13 宏晶微电子科技股份有限公司 信号处理方法、装置及系统

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4474753A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US5266562A (en) * 1987-11-19 1993-11-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-inflammatory agents
EP0436611A4 (en) * 1988-09-28 1992-03-11 Peptide Technology Ltd Compound and method for the retardation of collagen cross-linking
US5049655A (en) * 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
US5198423A (en) * 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
US6391343B1 (en) * 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
ES2110986T3 (es) 1991-08-12 1998-03-01 Nestle Sa Composicion alimenticia.
US5411943A (en) * 1992-02-25 1995-05-02 Biomeasure, Inc. Hepatoma treatment with somatostatin analogs
DE4316293C2 (de) * 1993-05-14 1996-05-09 Jobst Krauskopf Verwendung einer Kombination von Anserin/Carnosin und Hypotaurin/Taurin zur Bekämpfung entzündlicher Erkrankungen
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
TW360501B (en) 1996-06-27 1999-06-11 Nestle Sa Dietetically balanced milk product
DK0832565T3 (da) 1996-09-24 2000-11-20 Nestle Sa Mælkeerstatningsprodukt og fremgangsmåde til fremstilling deraf
EP0971957A1 (en) * 1997-03-26 2000-01-19 Novo Nordisk A/S Polypeptide with appetite regulating activity
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
EP1291022A1 (en) * 1998-07-30 2003-03-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Methods of using lanreotide, a somatostatin analogue
DE69919019T2 (de) 1998-11-24 2004-11-25 Société des Produits Nestlé S.A. Verfahren zur Herstellung einer Proteinzusammensetzung und einer diese enthaltenden Säuglingsnahrung
JP2000226400A (ja) * 1998-12-04 2000-08-15 Nippon Kayaku Co Ltd アポトーシス制御能を有する蛋白質、その遺伝子及びそれらの用途
CA2499211A1 (en) * 1999-05-17 2000-11-23 Conjuchem Inc. Modified peptides yy and conjugates thereof
WO2000072868A2 (en) * 1999-06-01 2000-12-07 Prendergast Patrick T Peptides for therapeutic use
EP1593384A3 (en) * 1999-06-29 2006-04-26 Palatin Technologies, Inc. Compositions for treatment of sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
WO2002051232A2 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
US6660756B2 (en) * 2001-03-28 2003-12-09 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
AU2002316221A1 (en) * 2001-05-16 2002-11-25 Nicholas P. Plotnikoff Methods for inducing sustained immune response
ES2287065T3 (es) 2001-11-23 2007-12-16 Societe Des Produits Nestle S.A. Proceso para la preparacion de leche en polvo y productos lacteos concentrados.
JP2003267992A (ja) * 2002-03-18 2003-09-25 Makoto Fujii 抗酸化剤、老化防止剤および／または抗ガン剤
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US8461119B2 (en) * 2002-09-24 2013-06-11 The Burnham Institute Agents that modulate Eph receptor activity
CN100381462C (zh) * 2002-11-27 2008-04-16 伊藤火腿株式会社 肽及含有所述肽的药物组合物
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
US20050101535A1 (en) * 2003-05-06 2005-05-12 Rosenstein David H. Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain
EP1638993A4 (en) * 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
US7468353B2 (en) * 2003-07-14 2008-12-23 Mondobiotech Laboratories Anstalt Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung diseases
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20070053954A1 (en) * 2003-10-24 2007-03-08 Rowe Stephen C Macromer-melt formulations
MXPA06012175A (es) * 2004-04-23 2007-03-28 Senju Pharma Co Promotor de neuritogenesis corneal que contiene polipeptido activador de la adenilato ciclasa de la pituitaria y sus derivados.
PL1797112T3 (pl) * 2004-09-29 2011-04-29 The Administrators Of The Tulane Educational Fund Inhibitory wirusa zapalenia wątroby typu C
WO2006059108A2 (en) * 2004-12-02 2006-06-08 Domantis Limited ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
WO2006119388A2 (en) * 2005-05-03 2006-11-09 Novetide, Ltd. Methods for the production of peptide having a c-terminal amide
CA2624153A1 (en) * 2005-09-29 2007-04-12 The Scripps Research Institute Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
WO2007060692A2 (en) * 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
EP2004211A4 (en) * 2006-03-17 2010-07-07 Stem Cell Therapeutics Corp DOSEERSCHEMATA FOR LH OR HCG AND EPO FOR THE TREATMENT OF NEUROLOGICAL DISEASES
UA22357U (en) * 2006-10-25 2007-04-25 Inst Surgery Transplantation Method for treatment of pancreatic pseudocyst and of parapancreatic liquid accumulation
WO2008086042A2 (en) * 2007-01-10 2008-07-17 Chisari Francis V Preventing infection by a measles or respiratory syncytial virus

Also Published As

Publication number Publication date
US20100216724A1 (en) 2010-08-26
WO2009033726A3 (en) 2009-09-11
WO2009039969A2 (en) 2009-04-02
CA2698666A1 (en) 2009-03-19
EP2192915A1 (en) 2010-06-09
WO2009043454A2 (en) 2009-04-09
KR20100063717A (ko) 2010-06-11
WO2009033712A2 (en) 2009-03-19
AU2008306130A1 (en) 2009-04-09
WO2009033664A1 (en) 2009-03-19
AU2008297927A1 (en) 2009-03-19
JP2011505335A (ja) 2011-02-24
WO2009033741A2 (en) 2009-03-19
WO2009033657A3 (en) 2009-06-04
ATE553772T1 (de) 2012-05-15
AU2008297915A1 (en) 2009-03-19
EP2190453A2 (en) 2010-06-02
KR20100061485A (ko) 2010-06-07
WO2009040022A3 (en) 2009-06-04
KR20100071984A (ko) 2010-06-29
EP2197477B1 (en) 2012-04-18
WO2009043518A3 (en) 2009-10-22
WO2009043454A3 (en) 2009-11-12
RU2010113989A (ru) 2011-10-20
EP2207560A2 (en) 2010-07-21
CA2710406A1 (en) 2009-04-09
WO2009033657A2 (en) 2009-03-19
JP5385276B2 (ja) 2014-01-08
WO2009033723A2 (en) 2009-03-19
WO2009040035A3 (en) 2009-07-16
US20100204132A1 (en) 2010-08-12
WO2009039978A2 (en) 2009-04-02
EP2187931A2 (en) 2010-05-26
RU2010114007A (ru) 2011-10-20
US20100210535A1 (en) 2010-08-19
WO2009033760A2 (en) 2009-03-19
WO2009033712A3 (en) 2009-11-05
JP2010538992A (ja) 2010-12-16
JP5395793B2 (ja) 2014-01-22
WO2009039978A3 (en) 2009-05-28
WO2009033726A2 (en) 2009-03-19
US20100204135A1 (en) 2010-08-12
RU2010114059A (ru) 2011-10-20
CA2698833A1 (en) 2009-03-19
CA2699047A1 (en) 2009-04-02
WO2009040035A2 (en) 2009-04-02
WO2009033771A2 (en) 2009-03-19
KR20100058546A (ko) 2010-06-03
WO2009039959A1 (en) 2009-04-02
CA2698912A1 (en) 2009-03-19
EP2197477A2 (en) 2010-06-23
US20100184679A1 (en) 2010-07-22
WO2009033760A3 (en) 2009-08-27
JP2010539061A (ja) 2010-12-16
JP2010539031A (ja) 2010-12-16
WO2009043518A2 (en) 2009-04-09
RU2010114034A (ru) 2011-10-20
WO2009033741A3 (en) 2009-09-03
KR20100058556A (ko) 2010-06-03
WO2009039958A1 (en) 2009-04-02
AU2008297535A1 (en) 2009-03-19
WO2009040022A2 (en) 2009-04-02
US20100204138A1 (en) 2010-08-12
WO2009033723A3 (en) 2009-09-03
JP2010539045A (ja) 2010-12-16
AU2008303940A1 (en) 2009-04-02
WO2009033771A3 (en) 2009-05-22
EP2187901A2 (en) 2010-05-26
EP2187901B1 (en) 2012-08-08
WO2009039969A3 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
RU2010114009A (ru) Применение rgdspasskp и необязательно ангиотензина ii в качестве терапевтических средств при лечении, например, инфекций s. pneumoniae
RU2010113969A (ru) Применение trp-6-трипторелина и d-leu6-лейпролида в качестве терапевтических средств
RU2010114061A (ru) ПРИМЕНЕНИЕ ПЕПТИДА His-Ser-Leu-Gly-Lys-Trp-Leu-His-Pro-Asp-Lys-Phe ИНДИВИДУАЛЬНО ИЛИ В КОМБИНАЦИИ С ПЕПТИДОМ Gly-Arg-Gly-Asp-Asn-Pro-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010113975A (ru) (D-Leu)-ГИСТРЕЛИН В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010113977A (ru) Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
RU2010114023A (ru) ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
RU2010114028A (ru) Применение ангиотензина ii в качестве терапевтического средства, например, при инфекции s. pneumoniae
RU2010113999A (ru) Применение секретина и необязательно уродилатина в качестве терапевтических средств
RU2010113985A (ru) Применение уродилатина в качестве терапевтического средства
RU2010114018A (ru) Применение пептид тимозина бета 4 индивидуально или в сочетании с цекропином а в качестве терапевтического средства
RU2010114044A (ru) Применение белка полосы 3 (824-829) и/или фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa
RU2010114045A (ru) Применение пептида sfllr-oh и мурамилдипептида в качестве терапевтических средств
WO2009033668A3 (en) Use of a peptide as a therapeutic agent
RU2010114051A (ru) Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств
RU2010114030A (ru) Применение пептида в качестве терапевтического средства
RU2010114010A (ru) Применение октреотида в качестве терапевтического средства
RU2010114050A (ru) Применение пептида рецептора il-1 индивидуально или в комбинации с октадециловым эфиром d-ala-gln в качестве терапевтического средства
RU2010114003A (ru) Применение пептида фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
RU2010114005A (ru) Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства
RU2010114037A (ru) Применение белка полосы 3 и расар-27 в качестве терапевтического средства
RU2010114060A (ru) Применение пептида в качестве терапевтического средства

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20110912